Sponsor Overview
Explore verified public information about Mesoblast's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 4 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“In certain circumstances, patients who do not qualify for clinical trials may seek access to Mesoblast’s investigational product candidates through Expanded Access. Mesoblast will evaluate each request on a case-by-case basis.”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 1 supporting sources.
Conditions: Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 4 supporting sources.
Conditions: Graft-Versus-Host Disease
Conditions: Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Conditions: Crohn's Disease
Conditions: Graft vs Host Disease, Graft-Versus-Host Disease
Reagan-Udall Foundation Insights
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.